Past Projects
Centre for Clinical Trials
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy and of ranibizumab (0.3mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration [more info]
An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD) [more info]
A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3mg and 0.5mg) administered as two dosing regimens in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration [more info]
Nepafenac 0,1% Eye Drops, suspension compared to ketorolac Trometamol 0,5% Eye Drops, solution and placebo (nepafenac vehicle) for the prevention and treatment of ocular inflammation and ocular pain associated with cataract surgery: european study [more info]
A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement [more info]
An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LARÒ in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR) [more info]
An open label evaluation of long term efficacy and safety of posterior juxtascleral injections of anecortave acetate 15mg in patients with subfoveal exudative age-related macular degeneration (AMD) [more info]
A phase 3B, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of macugenTM given every 6 weeks for 54 weeks (to be extended to 102 weeks as indicated), to MacugenTM plus PDT with VisudyneÒ, in subjects with predominantly classic subfoveal chorodial neovascularization (CMV) secondary to age-related macular degeneration (AMD) [more info]
A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO [more info]
Clinical Efficacy and safety of T1225 1.4% Eye Drops (3-Day Treatment) versus Tobramycin 0.3% Eye Drops (7-Day Treatment) in the treatment of purulent bacterial conjunctivitis [more info]